Aspirin is associated with an increased risk of subdural hematoma in normal-pressure hydrocephalus patients following shunt implantation

J Neurosurg. 2015 Aug;123(2):423-6. doi: 10.3171/2014.11.JNS14804. Epub 2015 Jan 2.

Abstract

Object: In this paper the authors investigate whether shunt-treated patients with normal-pressure hydrocephalus receiving aspirin therapy are at increased risk of developing subdural hematoma (SDH).

Methods: Records from 80 consecutive patients who had undergone implantation of a cerebrospinal fluid shunt for the treatment of normal-pressure hydrocephalus were retrospectively reviewed.

Results: Eleven cases of symptomatic SDH occurred, all among patients receiving aspirin or clopidogrel. The 5-year survival estimate was 0.3 (p < 0.0001) for users of aspirin and the hazard ratio was 12.8 (95% CI 3.1-53).

Conclusions: Patients on an aspirin therapy regimen have a markedly increased risk of SDH after a shunt has been implanted for the treatment of normal-pressure hydrocephalus. Users of clopidogrel may have an even greater risk.

Keywords: NPH = normal-pressure hydrocephalus; SDH = subdural hematoma; aspirin; cerebrospinal fluid shunt; normal-pressure hydrocephalus; subdural hematoma; traumatic brain injury.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aspirin / adverse effects*
  • Cerebrospinal Fluid Shunts / adverse effects*
  • Clopidogrel
  • Female
  • Fibrinolytic Agents / adverse effects*
  • Hematoma, Subdural / etiology*
  • Humans
  • Hydrocephalus, Normal Pressure / surgery*
  • Male
  • Middle Aged
  • Risk Factors
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives

Substances

  • Fibrinolytic Agents
  • Clopidogrel
  • Ticlopidine
  • Aspirin